GT Medical Technologies, Inc.

Key People

• Per Langoe - Chief Executive Officer
• Michael Garcia, MD, MS - Chief Medical Officer and Head of Clinical Development
• James Leech - Chief Financial and Strategy Officer
• Ole Mikkelsen, MBA - Chief Operating Officer
• Richard Low - Chief Marketing Officer
• Jeff Lewis - Chief Commercial Officer
• Brian Martin, MBA - Senior Vice President of Corporate Affairs and Investor Relations
• Ty Atteberry, MBA - Senior Vice President of Sales
• Anthony Smith - Senior Vice President of Operations
• David G. Brachman, MD, FASTRO - Co-Founder and Chief Technology Officer
• Heyoung McBride, MD - Co-Founder
• Peter Nakaji, MD - Co-Founder
• Theresa Thomas, MS, CCRC - Co-Founder

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in medical technology and healthcare.

The leadership team includes individuals with significant experience in the medical technology sector, enhancing the company's potential for success.

Clinical Need

Aspect: Very Strong
Summary: GammaTile addresses a critical need for effective post-surgical radiation therapy in brain tumor patients.

GammaTile provides immediate, localized radiation treatment at the time of tumor removal, targeting residual cancer cells while minimizing exposure to healthy brain tissue, addressing a critical need in brain tumor treatment.

Competition

Aspect: First mover
Summary: GammaTile offers a novel approach with limited direct competition in the market.

As a first mover, GT Medical Technologies has the advantage of establishing market presence but also faces the challenge of educating the market and driving adoption.

Technical Challenge

Aspect: Moderate
Summary: The integration of radiation seeds into a bioabsorbable implant presents moderate technical challenges.

Developing a bioabsorbable implant embedded with radiation seeds involves moderate technical complexity, necessitating precise engineering and regulatory compliance.

Patent

Aspect: Very Strong
Summary: The company holds multiple patents protecting its technology.

GT Medical Technologies has secured 10 US and 2 Canadian-issued patents, along with 1 EPO patent, providing robust intellectual property protection for its GammaTile technology.

Financing

Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.

GT Medical Technologies has raised substantial funding, including a $45 million Series C financing led by Gilde Healthcare Partners and a $35 million venture loan facility from Horizon Technology Finance Corporation, indicating strong investor confidence.

Regulatory

Aspect: 510k/PMA
Summary: GammaTile has received FDA 510(k) clearance for specific indications.

GammaTile has obtained FDA 510(k) clearance for the treatment of recurrent brain tumors and newly diagnosed malignant tumors, enabling its commercialization in the U.S. market.

Opportunity Rollup

Odds of Success

3.1

Peak Market Share

3.65

Segment CAGR

4.9%

Market Segment

Neurology Devices

Market Sub Segment

Brain Tumor Treatment Devices

Key Takeaway

GT Medical Technologies' GammaTile offers a novel solution for brain tumor treatment, addressing a significant clinical need with strong financial backing and patent protection, positioning the company for substantial market impact.